Takeda Pharma (TKPYY) 21.4200 $TKPYY
Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders
PR Newswire Europe - Wed Jun 08, 7:52AM CDT
Deal Provides Takeda Global Rights to Selective 5-HT4 Agonist; Highlights Takeda's Commitment to Gastroenterology as a Core Therapeutic Area
TBPH: 23.54 (+0.25)
Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women's Health and Prostate Cancer
PR Newswire - Mon Jun 06, 6:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) and Roivant Sciences Ltd. today announced the formation of Myovant Sciences Ltd. ("Myovant"
, a biopharmaceutical company focused on delivering innovative women's health and prostate cancer solutions by efficiently advancing new medicines to market that have the potential to improve the lives of millions of patients. In addition, Lynn Seely, MD, an endocrinologist who led the development of XTANDI® (enzalutamide) for the treatment of prostate cancer as the Chief Medical Officer of Medivation from 2005 to 2015, was named the President & Chief Executive Officer of Myovant Sciences, Inc.
Trintellix (vortioxetine) Now Available in U.S. Pharmacies
PR Newswire - Wed Jun 01, 9:00AM CDT
Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502), and Lundbeck announced today that Trintellix (vortioxetine), a once-daily oral antidepressant indicated for the treatment of major depressive disorder (MDD) in adults, is now available in United States pharmacies.
Takeda Receives Positive CHMP Opinion for ADCETRIS(R) (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
BusinessWire - Fri May 27, 7:30AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS(R) (brentuximab vedotin) and recommended its approval for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplantation (ASCT). On average 50 percent of Hodgkin lymphoma patients relapse after ASCT and those patients with additional risk factors can be at even higher risk of relapse. ADCETRIS after ASCT is a new treatment paradigm based on the largest randomized study ever conducted in relapsed or refractory Hodgkin lymphoma. The AETHERA Phase 3 trial is the first completed study that has explored consolidation treatment immediately following ASCT as a way of extending the effect of transplant for prevention of relapse among people with Hodgkin lymphoma. The use of ADCETRIS in this setting may provide a meaningful treatment option where none currently exist for patients.
Takeda Provides Update on EU Marketing Authorization Application for NINLARO(R) (ixazomib) in Relapsed/Refractory Multiple Myeloma
BusinessWire - Fri May 27, 7:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending against the authorization of NINLARO(R) (ixazomib) capsules, an oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. Takeda intends to appeal this opinion and request a re-examination by the CHMP.
Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting
PR Newswire Europe - Mon May 23, 11:49AM CDT
Takeda Pharmaceutical Company Limited [TSE: 4502 [http://www.takeda.com/investor-information/]], ("Takeda" today announced the oral presentations of two data analyses: one evaluating the optimal position of vedolizumab in the ulcerative colitis (UC) treatment paradigm, and a second separate analysis assessing whether early vedolizumab trough levels were associated with subsequent drug efficacy. Findings were presented during the 2016 Digestive Disease Week (DDW) Annual Meeting in San Diego, California, and were included in a total of 13 Takeda-sponsored vedolizumab or inflammatory bowel disease (IBD)-focused abstracts, including four oral presentations and nine posters.
Long-Term Integrated Safety Analysis Published in Gut Reports a Favorable Benefit-Risk Profile for Vedolizumab in an Extended Treatment Period
PR Newswire Europe - Thu May 12, 8:02AM CDT
This analysis examining treatment with vedolizumab in patients with moderately to severely active ulcerative colitis or Crohn's disease observed no significant safety concerns
Takeda Reports Results for Fiscal Year 2015 (April 2015 - March 2016) and Forecast for Fiscal Year 2016
BusinessWire - Tue May 10, 1:00AM CDT
Takeda Pharmaceutical Company Limited (TOKYO:4502):
Takeda Receives $38 Million Grant from the Bill & Melinda Gates Foundation to Support Polio Eradication in Developing Countries
BusinessWire - Sun May 08, 6:00PM CDT
Takeda Pharmaceutical Company Limited (TOKYO:4502), ("Takeda" today announced a partnership with the Bill & Melinda Gates Foundation to support global polio eradication in developing countries. With this funding, Takeda will develop, license and supply at least 50 million doses per year of Sabin-strain inactivated poliovirus vaccine (sIPV) to more than 70 developing countries. The vaccine will be manufactured at Takeda's facility in Hikari, Japan. This effort is aligned with Takeda's strategy to utilize innovation and partnerships to address critical unmet needs in global public health, and the Sustainable Development Goals adopted by the United Nations in September 2015.
Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:38AM CDT
Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.
ALNY: 69.88 (-1.17), GILD: 87.42 (-0.08), SNY: 41.40 (+0.10)
Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
PR Newswire - Mon May 02, 2:32PM CDT
Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502) (collectively "Takeda" , and Lundbeck announced today that Brintellix (vortioxetine) will be marketed in the United States under the new name Trintellix (vortioxetine) starting in June of 2016. The vortioxetine product is a prescription medicine approved to treat Major Depressive Disorder (MDD) in adults. The formulation, indication and dosages of Trintellix remain the same as that of Brintellix.
Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 1:09PM CDT
Seattle Genetics (SGEN) reported a loss of 15 cents per share, wider than the Zacks Consensus Estimate of a loss of 11 cents.
EBS: 43.95 (+0.10), SGEN: 42.39 (-0.04), AEGR: 1.60 (-0.08)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 7.07 (+0.16), CBMG: 15.27 (+0.05), OCAT: 8.47 (+0.01), ZBH: 119.76 (+0.33), PFE: 35.25 (+0.41), LLY: 74.91 (+0.21), GSK: 42.51 (-0.19), GLPG: 59.38 (+1.98), AXSM: 8.28 (+0.20), OMER: 11.02 (+0.23), CANF: 2.95 (-0.02), AST: 3.13 (-0.04), AKTX: 15.41 (+0.80)
Global Antibody Conjugates Drugs Market 2016-2020 - Key Vendors are F.Hoffmann-La Roche AG, Seattle Genetics & Takeda Pharmaceutical Company - Research and Markets
BusinessWire - Fri Apr 15, 3:36AM CDT
Research and Markets has announced the addition of the "Global Antibody Conjugates Drugs Market 2016-2020" report to their offering.
Takeda and Lundbeck Receive Complete Response Letter for Brintellix® (vortioxetine) sNDA
PR Newswire - Mon Mar 28, 7:02PM CDT
Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for the supplemental new drug application (sNDA) to include new data in the clinical trials section of the U.S. label of Brintellix® (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with major depressive disorder (MDD). The FDA approved Brintellix on September 30, 2013 for the treatment of MDD in adults. The CRL does not apply to the use of Brintellix in MDD.
New Data Presented at European Crohn's and Colitis Organisation (ECCO) Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment
PR Newswire Europe - Sat Mar 19, 3:19AM CDT
Analysis reported clinical improvements with up to 152 weeks of vedolizumab treatment seen in patients with moderately to severely active ulcerative colitis
Orexigen Buys U.S. Rights to Contrave, Inks Deal in the EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:50PM CDT
Orexigen (OREX) has regained U.S. rights to Contrave from Takeda Pharmaceutical and inked a deal with Valeant Pharmaceuticals to commercialize the drug in the EU.
OREX: 0.64 (+0.22), VRX: 23.92 (-0.72), AMAG: 22.10 (+0.05)
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United States
PR Newswire - Tue Mar 15, 6:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) (collectively "Takeda" , today announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE® (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for chronic weight management. Completion of the transaction is subject to the parties' receipt of clearance under the Hart-Scott-Rodino Antitrust Improvement Act.
OREX: 0.64 (+0.22)
Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders
PR Newswire Europe - Wed Jun 08, 7:52AM CDT
Deal Provides Takeda Global Rights to Selective 5-HT4 Agonist; Highlights Takeda's Commitment to Gastroenterology as a Core Therapeutic Area
TBPH: 23.54 (+0.25)
Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women's Health and Prostate Cancer
PR Newswire - Mon Jun 06, 6:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) and Roivant Sciences Ltd. today announced the formation of Myovant Sciences Ltd. ("Myovant"
, a biopharmaceutical company focused on delivering innovative women's health and prostate cancer solutions by efficiently advancing new medicines to market that have the potential to improve the lives of millions of patients. In addition, Lynn Seely, MD, an endocrinologist who led the development of XTANDI® (enzalutamide) for the treatment of prostate cancer as the Chief Medical Officer of Medivation from 2005 to 2015, was named the President & Chief Executive Officer of Myovant Sciences, Inc. Trintellix (vortioxetine) Now Available in U.S. Pharmacies
PR Newswire - Wed Jun 01, 9:00AM CDT
Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502), and Lundbeck announced today that Trintellix (vortioxetine), a once-daily oral antidepressant indicated for the treatment of major depressive disorder (MDD) in adults, is now available in United States pharmacies.
Takeda Receives Positive CHMP Opinion for ADCETRIS(R) (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
BusinessWire - Fri May 27, 7:30AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS(R) (brentuximab vedotin) and recommended its approval for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplantation (ASCT). On average 50 percent of Hodgkin lymphoma patients relapse after ASCT and those patients with additional risk factors can be at even higher risk of relapse. ADCETRIS after ASCT is a new treatment paradigm based on the largest randomized study ever conducted in relapsed or refractory Hodgkin lymphoma. The AETHERA Phase 3 trial is the first completed study that has explored consolidation treatment immediately following ASCT as a way of extending the effect of transplant for prevention of relapse among people with Hodgkin lymphoma. The use of ADCETRIS in this setting may provide a meaningful treatment option where none currently exist for patients.
Takeda Provides Update on EU Marketing Authorization Application for NINLARO(R) (ixazomib) in Relapsed/Refractory Multiple Myeloma
BusinessWire - Fri May 27, 7:00AM CDT
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending against the authorization of NINLARO(R) (ixazomib) capsules, an oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. Takeda intends to appeal this opinion and request a re-examination by the CHMP.
Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting
PR Newswire Europe - Mon May 23, 11:49AM CDT
Takeda Pharmaceutical Company Limited [TSE: 4502 [http://www.takeda.com/investor-information/]], ("Takeda"
today announced the oral presentations of two data analyses: one evaluating the optimal position of vedolizumab in the ulcerative colitis (UC) treatment paradigm, and a second separate analysis assessing whether early vedolizumab trough levels were associated with subsequent drug efficacy. Findings were presented during the 2016 Digestive Disease Week (DDW) Annual Meeting in San Diego, California, and were included in a total of 13 Takeda-sponsored vedolizumab or inflammatory bowel disease (IBD)-focused abstracts, including four oral presentations and nine posters. Long-Term Integrated Safety Analysis Published in Gut Reports a Favorable Benefit-Risk Profile for Vedolizumab in an Extended Treatment Period
PR Newswire Europe - Thu May 12, 8:02AM CDT
This analysis examining treatment with vedolizumab in patients with moderately to severely active ulcerative colitis or Crohn's disease observed no significant safety concerns
Takeda Reports Results for Fiscal Year 2015 (April 2015 - March 2016) and Forecast for Fiscal Year 2016
BusinessWire - Tue May 10, 1:00AM CDT
Takeda Pharmaceutical Company Limited (TOKYO:4502):
Takeda Receives $38 Million Grant from the Bill & Melinda Gates Foundation to Support Polio Eradication in Developing Countries
BusinessWire - Sun May 08, 6:00PM CDT
Takeda Pharmaceutical Company Limited (TOKYO:4502), ("Takeda"
today announced a partnership with the Bill & Melinda Gates Foundation to support global polio eradication in developing countries. With this funding, Takeda will develop, license and supply at least 50 million doses per year of Sabin-strain inactivated poliovirus vaccine (sIPV) to more than 70 developing countries. The vaccine will be manufactured at Takeda's facility in Hikari, Japan. This effort is aligned with Takeda's strategy to utilize innovation and partnerships to address critical unmet needs in global public health, and the Sustainable Development Goals adopted by the United Nations in September 2015. Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:38AM CDT
Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.
ALNY: 69.88 (-1.17), GILD: 87.42 (-0.08), SNY: 41.40 (+0.10)
Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
PR Newswire - Mon May 02, 2:32PM CDT
Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502) (collectively "Takeda"
, and Lundbeck announced today that Brintellix (vortioxetine) will be marketed in the United States under the new name Trintellix (vortioxetine) starting in June of 2016. The vortioxetine product is a prescription medicine approved to treat Major Depressive Disorder (MDD) in adults. The formulation, indication and dosages of Trintellix remain the same as that of Brintellix. Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 1:09PM CDT
Seattle Genetics (SGEN) reported a loss of 15 cents per share, wider than the Zacks Consensus Estimate of a loss of 11 cents.
EBS: 43.95 (+0.10), SGEN: 42.39 (-0.04), AEGR: 1.60 (-0.08)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 7.07 (+0.16), CBMG: 15.27 (+0.05), OCAT: 8.47 (+0.01), ZBH: 119.76 (+0.33), PFE: 35.25 (+0.41), LLY: 74.91 (+0.21), GSK: 42.51 (-0.19), GLPG: 59.38 (+1.98), AXSM: 8.28 (+0.20), OMER: 11.02 (+0.23), CANF: 2.95 (-0.02), AST: 3.13 (-0.04), AKTX: 15.41 (+0.80)
Global Antibody Conjugates Drugs Market 2016-2020 - Key Vendors are F.Hoffmann-La Roche AG, Seattle Genetics & Takeda Pharmaceutical Company - Research and Markets
BusinessWire - Fri Apr 15, 3:36AM CDT
Research and Markets has announced the addition of the "Global Antibody Conjugates Drugs Market 2016-2020" report to their offering.
Takeda and Lundbeck Receive Complete Response Letter for Brintellix® (vortioxetine) sNDA
PR Newswire - Mon Mar 28, 7:02PM CDT
Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for the supplemental new drug application (sNDA) to include new data in the clinical trials section of the U.S. label of Brintellix® (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with major depressive disorder (MDD). The FDA approved Brintellix on September 30, 2013 for the treatment of MDD in adults. The CRL does not apply to the use of Brintellix in MDD.
New Data Presented at European Crohn's and Colitis Organisation (ECCO) Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment
PR Newswire Europe - Sat Mar 19, 3:19AM CDT
Analysis reported clinical improvements with up to 152 weeks of vedolizumab treatment seen in patients with moderately to severely active ulcerative colitis
Orexigen Buys U.S. Rights to Contrave, Inks Deal in the EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:50PM CDT
Orexigen (OREX) has regained U.S. rights to Contrave from Takeda Pharmaceutical and inked a deal with Valeant Pharmaceuticals to commercialize the drug in the EU.
OREX: 0.64 (+0.22), VRX: 23.92 (-0.72), AMAG: 22.10 (+0.05)
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United States
PR Newswire - Tue Mar 15, 6:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) (collectively "Takeda"
, today announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE® (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for chronic weight management. Completion of the transaction is subject to the parties' receipt of clearance under the Hart-Scott-Rodino Antitrust Improvement Act. OREX: 0.64 (+0.22)
